However, cemiplimab, an antibody immunotherapy that inhibits programmed cell death protein-1 and is approved for the treatment of locally advanced or metastatic squamous cell carcinoma, should be considered in patients ineligible for curative surgery and/or radiotherapy. The gene discussed is PDCD1; the disease is metastatic squamous cell carcinoma.